EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study

Mieke R Van Bockstal, Gabriela Beniuga, Ligia Craciun, David Creytens, Franceska Dedeurwaerdere, Philippe Delvenne, Pieter Demetter, Bart De Wiest, Koen Dewinne, Lionel Habran, Patrick Pauwels, Ivan Theate und 3 weitere

Pathobiology · 2022 · 89 (6) · 393-406

DOI: 10.1159/000522426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathobiology, online erschienen am 29.03.2022. Verfasst von Mieke R Van Bockstal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cliniques Universitaires Saint-Luc (CUSL), Woluwé-Saint-Lambert, Brussels, Belgium. Hauptthemen laut MEDLINE: Neoplasms, Receptor Protein-Tyrosine Kinases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The neurotrophic tropomyosin-related kinase (NTRK) genes encode the tropomyosin receptor kinases (TRKs). Patients with solid tumors harboring an oncogenic NTRK fusion are eligible for treatment with TRK inhibitors. NTRK fusion is often associated with TRK overexpression. Pan-TRK immunohistochemistry (IHC) is used to screen for NTRK fusions, but immunoreactivity patterns are poorly defined.

Methods

Data on pan-TRK immunoreactivity patterns in 2,669 solid tumors (comprising carcinomas, sarcomas, and melanocytic lesions) were retrospectively collected by nine laboratories and comprised tumor type, percentage of pan-TRK-positive tumor cells, staining intensity, cytoplasmic, membrane and/or nuclear staining pattern, and the presence or absence of NTRK fusion.

Results

Overall, 2,457 tumors (92%) were pan-TRK negative and 212 neoplasms (8%) were pan-TRK positive. Twenty-two pan-TRK-positive tumors (0.8%) harbored an NTRK fusion, representing 10% of all pan-TRK-positive tumors. Cytoplasmic immunoreactivity was most often observed, followed by membrane immunoreactivity. Nuclear pan-TRK positivity was least frequent, but was most often (33%) associated with NTRK fusion.

Conclusion

Pan-TRK IHC can be used to screen for NTRK fusions, especially in commonly diagnosed solid tumors with low NTRK fusion prevalence. In case of pan-TRK immunoreactivity, regardless of its intensity and tumor cell percentage, subsequent molecular tests should be performed to formally confirm the presence or absence of NTRK fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptor Protein-Tyrosine KinasesHumansImmunohistochemistryReceptor, trkARetrospective StudiesSarcomaTropomyosinGene FusionEarly Detection of Cancer

Stichwörter der Autor:innen

Gene fusionImmunohistochemistryNeurotrophic tropomyosin-related kinaseNext-generation sequencingPan-tropomyosin receptor kinase

Substanzen

Receptor, trkATropomyosinReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, Cliniques Universitaires Saint-Luc (CUSL), Woluwé-Saint-Lambert, Brussels, Belgium.
  • Institute of Clinical and Experimental Research (IREC), Université Catholique de Louvain, Brussels, Belgium.
  • Institut de Pathologie et de Génétique (IPG), Charleroi, Belgium.
  • Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
  • Department of Pathology, Ghent University Hospital (UZG), Ghent University, Ghent, Belgium.
  • Cancer Research Institute Ghent, CRIG, Ghent University Hospital, Ghent University, Ghent, Belgium.

Zitieren

APA

Van Bockstal, M. R., Beniuga, G., Craciun, L., Creytens, D., Dedeurwaerdere, F., Delvenne, P., Demetter, P., De Wiest, B., Dewinne, K., Habran, L., Pauwels, P., Theate, I., Vander Borght, S., Van Der Steen, K., & Weynand, B. (2022). The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology, 89(6), 393-406. https://doi.org/10.1159/000522426

Vancouver

Van Bockstal MR, Beniuga G, Craciun L, Creytens D, Dedeurwaerdere F, Delvenne P, et al. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology. 2022;89(6):393-406. doi:10.1159/000522426

BibTeX
@article{VanBockstal2022,
  author = {Van Bockstal, Mieke R and Beniuga, Gabriela and Craciun, Ligia and Creytens, David and Dedeurwaerdere, Franceska and Delvenne, Philippe and Demetter, Pieter and De Wiest, Bart and Dewinne, Koen and Habran, Lionel and Pauwels, Patrick and Theate, Ivan and Vander Borght, Sara and Van Der Steen, Kris and Weynand, Birgit},
  title = {The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study},
  journal = {Pathobiology},
  year = {2022},
  volume = {89},
  number = {6},
  pages = {393--406},
  doi = {10.1159/000522426}
}
Kostenlos starten →